← All trials
NCT04988971
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Jul 1, 2022
- Completion date
- Dec 31, 2022
- First posted
- Aug 4, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- West China HospitalLead sponsor
- Sichuan UniversitySponsor investigator
- Sichuan UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.